Alexandrite laser is one of the most common methods of hair removal. Its utilization is gradually increasing due to easy accessibility and high effectiveness. However, the disuse of protective goggles during the application of this laser is a serious problem. In this case report, we presented a 35-year-old male patient who had foveal injury by alexandrite laser. The inflammatory process secondary to the foveal injury and subsequent macular edema were treated with Ozurdex because of its potent antiedematous effect.

BACKGROUND:This study aimed to evaluate 1-year follow-up results of cases that were diagnosed with open globe injury (OGI), to compare trauma-related characteristics between pediatric and adult cases, and to determine risk factors for a poor final visual acuity.

Purpose. To evaluate the peripapillary retinal nerve fiber layer (RNFL) thicknesses of patients treated with intravitreal Ozurdex implant due to branch retinal vein occlusion (BRVO) related macular edema (ME). Methods. Thirty-three eyes of 33 patients treated with Ozurdex implant due to ME associated with BRVO were included in the study. Ophthalmic examinations including determination of best corrected visual acuity (BCVA), measurement of intraocular pressure (IOP), and central macular thickness (CMT) and peripapillary RNFL assessment with optical coherence tomography (OCT) were performed before the injection of Ozurdex implant and during the 6-month follow-up period after the injection. Results. The mean age was 55.2 ± 7.4 (range: 40–68) years. The BCVAs were significantly increased and CMTs were significantly decreased at month 3 and month 6 visits compared to baseline values. The mean IOP was significantly increased from baseline at day 1, week 1, and month 1 visits (p 1 = 0.008, p 2 = 0.018, and p 3 = 0.022, resp.). The average and inferior quadrant peripapillary RNFL thicknesses were significantly reduced at month 6 control visit compared to baseline values (both p < 0.001). Conclusions. Ozurdex implant improved the BCVA and reduced the CMT in the eyes with RVO related ME. However, IOP elevations occurred within the first month after the injection and the average and inferior quadrant RNFL thinning was found six months after the injection. Further controlled studies are warranted.

Ö ÖZ ZE ET T A Am ma aç ç: : Psödofakik hastalarda arka kapsül kesafeti nedeni ile neodimyum: yitriyum-alü-minyum-garnet (Nd: YAG) lazer kapsülotomi uygulanan hastaların refraktif değişimlerinin değerlendirilmesidir. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi Göz Kliniğinde arka kapsül kesafeti saptanan 38 hastanın 50 gözüne Nd: YAG lazer arka kapsü-lotomi uygulandı. Kapsülotomi öncesi ile kapsülotomi sonrası birinci hafta ve birinci ay hastaların en iyi düzeltilmiş görme keskinliği (EİDGK) sonuçları ve refraktif değişiklikleri karşılaştırıldı. .17 D respectively in first month after laser. While the reduction of mean cylindrical value was significant (p<0.001), there was no statistically significant change in the mean spherical value (p=0.79). Best corrected visual acuity of the patients according to Snellen was established baseline, first week and first month after laser as 0.30±0.17, 0.78±0.23, 0.81±0.34 respectively. There were statistically significant differences in BCVA of patients compared to those of prior to laser. In addition, there were no statistically significant differences in BCVA of patients between first week and month values (p>0.05). C Co on nc cl lu us si io on n: : Nd: YAG laser capsulotomy is an effective and safe method of treatment of posterior capsular opacification. Significant changes particularly in cylindrical refractive values after laser have been seen. These changes are fixed from the first week after laser.

Purpose:To investigate the effect of Ozurdex (dexamethasone intravitreal implant) on multifocal electroretinography (mfERG) findings during the treatment of macular edema secondary to the central retinal vein occlusion (CRVO).Methods:Fifteen eyes of 15 patients who were treated with Ozurdex implant due to CRVO-related macular edema were included in this study. Best corrected visual acuity (BCVA), central macular thickness (CMT), and mfERG evaluations were performed for all patients before injection of Ozurdex. After the injection, BCVA and CMT were measured at months 3 and 6 and mfERG test was performed at month 6 for all patients.Results:Pre-implantation mfERG P wave amplitude values of r1, r2, r3, r4 and r5 were 57.8 ± 14.8, 25.1 ± 10.6, 17.2 ± 7.3, 12.0 ± 5.0 and 7.1 ± 3.6 nV/deg2, respectively. They increased to 72.9 ± 33.2, 31.2 ± 9.3, 22.6 ± 7.6, 15.6 ± 7.1 and 10.9 ± 5.7 nV/deg2, respectively, at month 6. However, these increases were not statistically significant (all P > 0.05). Pre-implantation mfERG r1, r2, r3, r4 and r5 P wave implicit times were 40.1 ± 10.9, 39.4 ± 3, 38.4 ± 3.4, 38.2 ± 3.1 and 39.3 ± 2.2 ms, respectively and these values were measured as 38.9 ± 8.2, 38.4 ± 4.7, 37 ± 3.8, 37.5 ± 4.6 and 37.7 ± 4.7 ms at 6 months. Although there were reductions in P wave implicit times in all rings, they were not statistically significant (all P > 0.05).Conclusion:In this prospective study, we found that the Ozurdex implant had no effect on mfERG findings 6 months after insertion for treatment of CRVO-related macular edema.